
|Videos|November 12, 2021
Bausch + Lomb: Update on FDA approval of XIPERE for macular edema associated with uveitis
Author(s)David Hutton, Alex Delaney-Gesing
Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.
Advertisement
Ophthalmology Times'® David Hutton speaks with Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, on the company's latest
XIPERE is the first—and currently only— FDA-approved therapy utilizing suprachoridal administration.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Q&A: What’s in the glaucoma treatment pipeline?
2
FDA grants single-patient expanded access for urcosimod in neuropathic corneal pain
3
Low-dose pilocarpine shrinks pupil without altering accommodation in presbyopia
4
2026 from an OD's perspective: What is on the horizon
5



























